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AdvancedDespite recent breakthroughs in treatment of advanced thyroid cancers, prognoses remain poor.
Treatment of advanced, progressive disease remains challenging, with limited treatment options.
Small-molecule tyrosine kinase inhibitors, including vandetanib, cabozantinib, sorafenib, and lenvatinib,
which are now FDA-approved for thyroid cancer, have shown clinical benefit in advanced thyroid cancer.
Lenvatinib is approved for treatment of locally recurrent or metastatic, progressive, radioactive iodine
(RAI)-refractory differentiated thyroid cancer (DTC). It has been studied in phase II and III trials for treat-
ment of advanced RAI-refractory DTC, and in a phase II trial for medullary thyroid cancer (MTC).
Lenvatinib targets vascular endothelial growth factor receptors 1–3 (VEGFR1–3), fibroblast growth factor
receptors 1–4 (FGFR-1–4), RET, c-kit, and platelet-derived growth factor receptor a (PDGFRa). Its antitu-
mor activity may be due to antiangiogenic properties and direct antitumor effects. Lenvatinib has demon-
strated antitumor activity in a variety of solid tumors, including MTC, in phase I and II clinical trials. In a
phase II study in advanced RAI-refractory DTC, lenvatinib-treated patients achieved a 50% response rate
(RR), with median progression-free survival (PFS) of 12.6 months. In a phase III trial in RAI-refractory DTC,
median PFS in lenvatinib-treated patients was 18.3 months, with a 65% overall RR, versus 3.6 months in
placebo-treated patients, with a 2% RR. Adverse events occurring in >50% of patients included
hypertension, diarrhea, fatigue/asthenia, and decreased appetite. Lenvatinib is a promising new agent
for treatment of patients with advanced thyroid cancer.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
The incidence of thyroid cancer is increasing in the United
States [1]. Average annual percentage increases from 2006 to
2010 for thyroid cancers were 5.4% for men and 6.5% for women,
some of the largest annual increases among cancers [1]. Thyroid
cancer can be divided into 3 primary histologic types—differenti-
ated, medullary, and anaplastic—and these histologic subtypes
have different characteristics and prognoses. Differentiated thyroid
cancers (DTCs) account for about 95% of all thyroid cancer cases
and can be subdivided into 2 major histologic subtypes (papillary
thyroid carcinoma and follicular thyroid carcinoma) [2]. Medullary
thyroid cancers (MTCs) account for about 4% of all thyroid cancers
[2–4]. Sporadic MTC usually presents in the 5th or 6th decade of
life, and these make up approximately 80% of cases, while heredi-
tary MTC typically presents in the 2nd–3rd decade of life [3–5].Anaplastic thyroid cancers (ATCs) are the most aggressive form
of the disease. Anaplastic thyroid cancers account for <2% of all
thyroid cancers and typically occur in older patients, with a mean
age of 71 years [2].
Across all thyroid cancers, 5-year relative survival rates are high
at about 98%; however, about 30% of patients have disease recur-
rence [1,2]. Unfortunately, the prognosis remains poor for patients
with unresectable, advanced, or refractory DTC and MTC, with
median 10-year survival rates of 40–42%; survival rates are dismal
for ATC patients, who often die within 1 year of diagnosis [2,4,6].
Currently, treatment of recurrent DTC and MTC may include
surgical resection of cervical disease and localized therapies tar-
geted at metastatic sites. Radioactive iodine (RAI) therapy is used
in DTC; however, many patients are refractory to RAI, and alterna-
tive options for treatment remain limited [5].
Treatment with small molecule inhibitors or systemic therapy
may be considered for thyroid cancer patients, in particular, those
with progressive, clinically significant, or symptomatic disease
which cannot be managed with other strategies [5]. Vandetanib
and cabozantinib are FDA approved for patients with progressive,
metastatic, or unresectable MTC. Sorafenib and lenvatinib are
FDA approved for patients with RAI-refractory DTC.
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surgery
Although radioiodine ablation following thyroidectomy is stan-
dard treatment in patients with metastatic DTC, about 25–50% of
patients with locally advanced or metastatic disease become
refractory to RAI therapy [7,8]. Cytotoxic chemotherapy has a lim-
ited role in the management of DTC or MTC [8] and is associated
with low response rates (RRs) and significant side effects. Cytotoxic
chemotherapeutic agents have included doxorubicin, cisplatin,
bleomycin, and etoposide [9]. Conventional cytotoxic chemother-
apy has not been shown to prolong survival.
External beam radiation therapy (EBRT) has a limited role in
patients with advanced DTC or MTC, and it is not commonly used
[10]. Retrospective studies have reported variable findings, and the
role of EBRT remains controversial. Current National Comprehen-
sive Cancer Network (NCCN) and American Thyroid Association
(ATA) guidelines suggest that EBRT should be considered for
patients with unresectable locally advanced DTC or MTC to opti-
mize locoregional control [5,11,12]. EBRT may also be considered
for patients with distant metastases, which are painful or threaten-
ing vital structures, such as the brain and spinal cord. Treatment
options are limited for those with progressive disease that cannot
be managed with localized therapies such as radiation, which
underscores the need for new treatment options in patients with
advanced thyroid cancer. A comprehensive review of localized
therapies for the management of metastatic, RAI-refractory DTC
is beyond the scope of this review and can be found elsewhere [13].Systemic therapy: rationale for targeting tyrosine kinases
There are a number of intracellular molecular pathways that
contribute to the development of advanced thyroid cancer and cell
surface receptors that modulate the growth of these tumors
through those pathways (Fig. 1). The most common mutations inFig. 1. Signaling pathways in thyroid cancer [18]. AKT = protein kinase B; EGFR
PI3K = phosphatidylinositol-3 kinase; PTC = papillary thyroid carcinoma; RET = rearra
Adapted with permission Haugen and Sherman [18].differentiated primary thyroid cancers are mutations along the
Ras–Raf–MEK–ERK (MAPK), such as RAS and BRAF mutations. In
papillary thyroid carcinomas, signaling differences between RAS-
driven and BRAFv600E-driven tumors have been observed, with
BRAFv600E-like tumors signaling preferentially through MAPK and
RAS-like tumors signaling through both MAPK and phosphatidyl-
inositol-3 kinase (PI-3K) [14]. Mutations along the PI-3K pathway
are also more commonly seen in advanced differentiated, poorly
differentiated, and anaplastic thyroid cancers. However, gene
amplifications in several tyrosine kinase receptors have also been
described. In medullary thyroid cancer, mutations in RET have
been described in 88% of cases with inherited MTC types [5] and
RAS mutations have been described in 69% of RET wild-type cases
and 2.5% of RET-positive sporadic MTC cases [15]. Overexpression
of HGF and its receptor, MET, has also been reported [16–21].
Papillary tumors with BRAF mutations are associated with sig-
nificantly reduced expression of genes involved in the metabolism
of iodine, including genes for the sodium/iodide symporter (NIS),
apical iodide transporter (AIT-B), thyroglobulin (Tg), and thyroper-
oxidase (TPO). BRAF-mutated papillary tumors also exhibit higher
glucose transporter type 1 (Glut-1) transcript levels [22]. These dif-
ferences may play a role in tumor dedifferentiation and reduce the
efficacy of radioiodine [22]. In patients undergoing total thyroidec-
tomy for papillary tumors, BRAF mutations were associated with
extrathyroidal extension, thyroid capsular invasion, lymph node
metastasis, and increased disease persistence and recurrence
[23]. BRAFmutations have also been associated with higher clinical
stage, age at diagnosis, and tumor volume [24,25].
Although the MAPK pathway is activated in primary well-
differentiated thyroid cancers as well as poorly differentiated and
metastatic thyroid cancers, the PI3K pathway is preferentially acti-
vated in advanced thyroid cancers, supporting the development of
advanced disease, as tumors may acquire additional mutations
[18]. Inhibition of the MAPK pathway through MEK inhibition in
tumors with various MAPK genotypes inhibits cell proliferation,
induces cell cycle arrest, inhibits cancer cell invasion, and abolishes= epidermal growth factor receptor; mTOR = mammalian target of rapamycin;
nged during transfection; VEGFR = vascular endothelial growth factor receptor.
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way through Akt inhibition also inhibits cell proliferation [26,28].
Inhibition of the MAPK and either the PI3K or NF-jB pathways syn-
ergistically inhibits cell proliferation [26,27].MAPK and PI3K inhibi-
tion also synergistically induces non-apoptotic cell death [27].
VEGF is an important cytokine for the growth and proliferation
of tumors and is associated with the formation of new blood ves-
sels for tumors, increased tumor proliferation, and the growth of
tumor cells [29,30]. The intracellular activity of the VEGF receptor
is mediated by receptor tyrosine kinases [29]. Inhibition of the tyr-
osine kinase domain of the VEGF receptor leads to inhibition of
tumor cell growth [30].
The fibroblast growth factor receptor (FGFR) pathway is an
important signaling pathway for tumor proliferation in thyroid
cancers, and inhibition of FGFR in mice with a xenograft of a
human DTC cell line, R082-W-1, using a specific FGFR kinase inhi-
bitor, led to significant antitumor activity [31]. Selective FGFR
kinase inhibition also inhibited proliferation of human DTC cell
lines in vitro [31]. When lenvatinib was tested, it inhibited FGFR
signaling pathways in R082-W-1 cells in vitro, as measured by
Western blotting [31]. Overall, these data suggest that both atten-
uation of an FGFR signaling pathway and antiangiogenesis through
VEGFR may lead to antitumor effects [31].
The intracellular activities of signaling pathways important for
development and growth of thyroid cancers, e.g., the MAPK,
Pax8-PPAR, PI3K, and Akt pathways, are modulated by receptor
tyrosine kinases associated with cell surface receptors such as
VEGFR and EGFR (Fig. 1). Inhibition of VEGFR and other cellular
receptors can lead to inhibition of these intracellular pathways.
As an example of the importance of oncogenes and tyrosine
kinases, alterations in RET associated with thyroid cancer lead to
constitutive activation of ligand-independent kinases [32]. Inhibi-
tion of the RET oncogene by a tyrosine kinase inhibitor (TKI) pre-
vented proliferation and tumorigenicity of thyroid cancer cells
[32]. The importance of the RET receptor tyrosine kinase as a cen-
tral mediator of the processes that lead to the development and
progression of thyroid cancer provided the rationale for studying
multikinase inhibitors (specifically, those which target RET) in
MTC [5]. It is still unclear if targeting RET versus other cellular
receptors, particularly VEGFR, is the primary mechanism by which
multikinase inhibitors lead to clinical responses. While specific
inhibitors, such as inhibitors of RAS, BRAF, MEK, PI3K, mTOR, and
Akt, are potential therapies, these agents are not yet approved
for use in this disease, and multikinase inhibition is the primary
therapeutic approach [5,18].
Role of targeted therapies in thyroid cancer
Vandetanib and cabozantinib are approved by the FDA for treat-
ing advanced MTC. Sorafenib and lenvatinib are FDA approved for
the treatment of RAI-refractory advanced DTC. The receptor targetsTable 1
FDA-approved multikinase inhibitors approved for patients with advanced MTC and DTC.
Drug Indication Primary
Vandetanib [38] Symptomatic or progressive metastatic
or unresectable locally advanced MTC
RET, VEG
Cabozantinib [39] Progressive, metastatic MTC MET, VE
Sorafenib [34] Locally recurrent or metastatic progressive DTC VEGFR1-
Lenvatinib [41] Locally recurrent or metastatic, progressive,
RAI-refractory DTC
VEGFR, F
BRK = breast tumor kinase; c-kit = receptor for stem cell factor; DTC = differentiated th
receptor; MTC = medullary thyroid cancer; PDGFR = platelet-derived growth factor re
during transfection; SCFR = stem cell growth factor receptor; VEGFR = vascular endothel
* Estimated PFS; PFS not reached by data cutoff.and results from clinical trials of these drugs are summarized in
Table 1. All 4 of them were approved based on statistically signif-
icant increases in progression-free survival (PFS), not increased
overall survival [33–37].
The efficacy and safety of vandetanib were evaluated in an
international, randomized, placebo-controlled, double-blind phase
III trial (ZETA) in patients with locally advanced or metastatic MTC
[38]. Progressive disease was not a requirement for study entry and
patients were permitted to cross-over to the treatment arm if they
were randomized to placebo at the time of progression. This trial
randomized patients 2:1 to daily vandetanib or placebo, and it
showed a median PFS of 19.3 months for patients receiving placebo
and estimated PFS of 30.5 months for patients receiving vande-
tanib, with the median not being reached by the data cutoff (haz-
ard ratio [HR] 0.46, P < 0.001) [38]. Grade 3 adverse effects
occurring in >5% of patients receiving vandetanib included diar-
rhea, hypertension, QT interval prolongation, and fatigue [37,38].
The efficacy and safety of cabozantinib were determined in an
international, double-blind, randomized, placebo-controlled phase
III trial (EXAM) in patients with progressive metastatic or unre-
sectable MTC, with PFS as the primary endpoint [39]. Cross-over
to treatment was not permitted. The trial randomized patients to
either cabozantinib or placebo, with a median PFS of 11.2 months
in patients receiving cabozantinib versus 4.0 months in patients
receiving placebo (HR 0.28, P < 0.001) [39]. The most frequent
grade 3 or 4 adverse events in patients receiving cabozantinib were
diarrhea, palmar-plantar erythrodysesthesia, and fatigue [39]. A
recent subanalysis of cabozantinib in patients with 918 RET-
mutated tumors showed an overall survival advantage in this pop-
ulation [37,40].
The efficacy and safety of sorafenib in progressive metastatic,
RAI-refractory, targeted therapy-naïve DTC were evaluated in a
double-blind, multicenter phase III trial (DECISION) that random-
ized patients 1:1 to sorafenib or placebo, with PFS as the primary
endpoint [34]. Patients receiving sorafenib had a median PFS of
10.8 months compared with 5.8 months for patients receiving pla-
cebo. The most common treatment-emergent adverse events of
any grade occurring in >40% of patients receiving sorafenib were
hand-foot skin reaction, diarrhea, alopecia, rash, fatigue, loss of
weight, and hypertension [34,37].
The efficacy and safety of lenvatinib in progressive RAI-
refractory DTC were evaluated in a double-blind, multicenter
phase III trial (SELECT) that randomized patients 2:1 to lenvatinib
or placebo, with PFS as the primary endpoint [37,41]. Patients pre-
viously treated with VEGF-based therapies were included in this
trial. Results are summarized below (see ‘‘Clinical Trials with Len-
vatinib in Thyroid Cancer”).
Due to the importance of a range of tyrosine kinase families in
thyroid cancer, other kinase inhibitors have been studied in several
phase I and II clinical trials, and clinical trials with kinase inhibitors
in DTC are summarized in Table 2 [37,42–49]. Most of these kinasetargets for trial rationale Phase Total number
of patients
PFS (months)
FR, BRK, TIE2, EPH, Src III 331 30.5*
GFR2, RET III 330 11.2
3, RET, RAF, PDGFRb III 417 10.8
GFR, PDGFRa, RET, c-kit, SCFR III 392 18.3
yroid cancer; EPH = ephrin receptor; FGFR = fibroblast growth factor cell surface
ceptor; PFS = progression-free survival; RAI = radioactive iodine; RET = rearranged
ial growth factor receptor.
Table 2
Kinase inhibitors in phase I and II clinical trials in patients with advanced DTC.*
Drug Primary targets for trial rationale Phase Total number of patients RR (%) PFS (months)
Multikinase inhibitors
Axitinib [42] VEGFR, PDGFR, c-kit II 60 30 18.1
Motesanib [43] VEGFR, PDGFR, c-kit II 93 14 9.3
Sunitinib [44] PDGFR, FLT3, c-kit, VEGFR, RET II 35 31 12.8
Pazopanib [45] VEGFR, PDGFR, c-kit II 37 49 11.7
Vandetanib [46] RET, VEGFR, EGFR II 145 8 11.1
Cabozantinib [47] MET, VEGFR2, RET I 15 53 ND
Selective BRAF inhibitors
Dabrafenib [48] BRAF I 14 29 11.3
Vemurafenib [49] BRAF II 51 35 15.6
c-kit = receptor for stem cell factor; DTC = differentiated thyroid cancer; EGFR = epidermal growth factor receptor; FLT = FMS-like tyrosine kinase; ND = not determined;
PDGFR = platelet-derived growth factor receptor; PFS = progression-free survival; RET = rearranged during transfection; RR = response rate; VEGFR = vascular endothelial
growth factor receptor.
* This table is not for between-trial comparative purposes.
Table 3
Kinase inhibitory profile of lenvatinib [58].
Kinase IC50 (nM)
VEGFR1 22
VEGFR2 4.0
VEGFR3 5.2
FGFR1 46
PDGFRa 51
PDGFRb 39
EGFR 6500
c-kit 100
c-kit = receptor for stem cell factor; EGFR = epidermal growth factor receptor;
FGFR = fibroblast growth factor cell surface receptor; IC50 = half maximal inhibitory
concentration; PDGFR = platelet-derived growth factor receptor; VEGFR = vascular
endothelial growth factor receptor.
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derived growth factor receptor (PDGFR), c-kit, RET, and FLT3. The
PFS in these trials ranged from 9.3 months to over 18 months.
Vemurafenib is a BRAF kinase inhibitor that was tested in an
open-label, multicenter phase II clinical trial in patients with meta-
static or unresectable papillary thyroid cancer with a BRAF V600
mutation that is resistant to RAI [49]. This trial enrolled 51 patients
to receive 960 mg vemurafenib orally twice daily until disease
progression or unacceptable toxicity. Patients were divided into 2
cohorts: TKI-naïve and previously treated patients. Of the 26 evalu-
able treatment-naïve patients, 9 (35%) experienced a partial
response. Median PFS in this group was 15.6 months. In the previ-
ously treated cohort, 26% of the 25 evaluable patients achieved a
partial response. Median PFS was only 7 months in the pre-
treated cohort [37]. Among 17 patients receiving vemurafenib
outside a clinical trial, 47% had a partial response and 53% had
stable disease [50]. This drug has also been evaluated in a small
number of BRAF mutated ATC patients [51]. Of 7 patients reported,
2 obtained objective responses.
Dabrafenib, a BRAF kinase inhibitor, was studied in a phase I
trial which included 14 patients with BRAF-mutated thyroid
cancer. Four patients (29%) achieved a partial response [48]. This
drug has also been studied in the context of redifferentiation of
RAI-refractory disease [52]. Dabrafenib is being studied in thyroid
cancer in a phase I trial in combination with lapatinib [53]. Patients
enrolled in this trial will have a thyroid cancer resistant to RAI and
a BRAF V600E mutation. Dabrafenib is also being studied in combi-
nation with trametinib in 2 phase II trials. One of these trials is
studying dabrafenib with or without trametinib and is enrolling
patients with DTC (NCT01723202) [54]. The other trial is enrolling
patients with rare cancers with BRAF V600E mutations, including
anaplastic thyroid cancer (NCT02034110) [55].Lenvatinib mechanism of action
Because of the known role of tyrosine kinase pathways in the
development of thyroid cancer, and following the encouraging
results with multitargeted tyrosine kinase inhibition as a treat-
ment, lenvatinib was developed. Lenvatinib targets VEGFR1-3,
fibroblast growth factor receptors 1–4 (FGFR1–4), RET, c-kit,
PDGFRa, and mast/stem cell growth factor receptor (SCFR) in a
variety of preclinical tumor models [56–58], and one of its poten-
tial advantages may be its broad-spectrum antitumor activity. Len-
vatinib is a potent inhibitor of FGFR1, which differentiates it from
other currently available TKIs with angiogenesis properties, and
has significant antiangiogenic effects via inhibition of VEGFR2,
VEGFR3, and FGF1 [59]. The inhibitory profile of lenvatinib for
various kinases is listed in Table 3 [58]. Lenvatinib inhibited theprogression of 3 malignant pleural mesothelioma (MPM) cell lines,
which were orthotopically implanted in severe combined immun-
odeficient (SCID) mouse models [59]. In these mouse models, treat-
ment with lenvatinib inhibited VEGF-mediated angiogenesis, with
significantly lower microvessel density in treated mice (P < 0.01).
Treatment with lenvatinib prolonged survival of MPM cell-
bearing mice (P < 0.001). In a small cell lung cancer xenograft
mouse model, lenvatinib caused inhibition of tumor growth and
regression of tumors via inhibition of SCF-induced and c-kit-
induced angiogenesis [58]. In this mouse model, lenvatinib demon-
strated more potent antitumor effects than imatinib, which slowed
tumor growth but did not affect tumor regression. The investiga-
tors suggested that lenvatinib may inhibit angiogenesis by
decreasing mature endothelial cells and the KDR-mediated and
c-kit-mediated recruitment of circulating endothelial cells from
bone marrow into the circulation.
Lenvatinib may also act via direct antitumor effects. In vitro
studies using 2 human tumor cell lines demonstrated that lenva-
tinib inhibits tumor cell invasion and migration [60]. Cellular inva-
sion was reduced by 45% at 1 lM lenvatinib and to 13% by 10 lM
lenvatinib [60]. Inhibition of cellular migration by lenvatinib may
occur via inhibition of FGFR1 and PDGFRa signaling, which was
shown to be required for cellular migration. Cellular proliferation
assays conducted using 6 different human tumor cell lines demon-
strated that lenvatinib did not have an effect on cellular prolifera-
tion. Lenvatinib was evaluated in preclinical models of RET gene
fusions, which are current transmembrane tyrosine kinase onco-
genes. In cellular assays, lenvatinib inhibited the growth of 3
human cancer cell lines with RET gene fusions, i.e., KIF5B-RET,
CCDC6-RET, and NCOA4-RET [56]. Lenvatinib suppressed the growth
of CCDC6-RET human thyroid and lung cancer cell lines and
anchorage-independent growth and tumorigenicity of RET gene
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mouse model, treatment with lenvatinib daily for 10 days sup-
pressed the growth of tumors from NIH3T3/KIF5B-RET and signif-
icantly decreased microvessel density [56].
Lenvatinib is rapidly absorbed, extensively metabolized, and
excreted in urine and feces [61]. In a pharmacokinetic and excre-
tion study of a single oral 24 mg lenvatinib dose, peak plasma con-
centrations of lenvatinib were reached at 1.6 h after administration
[61]. The terminal half-life of lenvatinib was 34.5 h. Lenvatinib
undergoes extensive metabolism, with unchanged lenvatinib in
urine and feces accounting for 2.5% of the dose. Lenvatinib is elim-
inated by multiple pathways including metabolism by cytochrome
P450s and aldehyde oxidase and conjugation with glutathione
[62]. Based on drug–drug interaction and metabolic studies, lenva-
tinib has a low possibility of drug-drug interactions [62,63]. Lenva-
tinib exposure is slightly increased by ketoconazole and by P-gp
inhibition with rifampicin but is not likely clinically meaningful
[63,64]. In patients with severe hepatic impairment, a dose reduc-
tion from 24 mg to 14 mg is warranted [65].Lenvatinib clinical trials
Phase I dose-escalation and biomarker analysis
Several phase I studies have demonstrated a benefit of lenva-
tinib in patients with a variety of advanced solid tumors. In a phase
I dose-escalation study with biomarker analysis, lenvatinib was
evaluated in patients with advanced solid tumors resistant to stan-
dard therapy or for which no therapy was available, performance
status of Eastern Cooperative Oncology Group (ECOG) < 2, and life
expectancy of >3 months [66]. This was a sequential, dose-
escalation, open-label phase I study. Lenvatinib was administered
twice daily in a 2-week-on/1-week-off 28-day cycle. Dosing began
at 0.5 mg twice daily. The primary endpoint of the study was to
determine the maximum tolerated dose (MTD) and dose-limiting
toxicities of lenvatinib. The secondary endpoints included pharma-
cokinetics, safety, and tolerability of lenvatinib, antitumor
response, and establishing a dose for use in phase II trials. Explora-
tory endpoints included biomarker analysis of antitumor activity.
Plasma angiogenic proteins, circulating endothelial cells, and circu-
lating progenitor cells were measured for biomarker analysis.
Twenty-seven patients were included in the study. Dose-limiting
toxicities included a grade 3 AST/ALT increase in 1 patient at the
16 mg twice-daily dose and a grade 3 platelet count decrease in
2 patients at 20 mg twice daily. Therefore, the MTD was deter-
mined to be 13 mg twice daily. Antitumor activity was observed
in 22 patients. One patient had a partial response, and 84% of
patients had stable disease as the best response. Biomarker analy-
sis suggested that antiangiogenic activity correlated with thera-
peutic effect in this patient population. Baseline levels of SDF1,
c-kit(+), circulating endothelial progenitor cell (CEP) number, and
c-kit(+) ratio in circulating endothelial cells (CEC) were correlated
with treatment duration. The investigators suggest that high levels
of these biomarkers (as opposed to lower levels) at baseline may
predict tumor resistance [66].Phase I study of lenvatinib in patients with advanced solid tumors
The safety and tolerability of lenvatinib were evaluated in 82
patients with advanced solid tumors refractory to conventional
treatments. The majority of patients had sarcoma, melanoma,
and colorectal and renal cancers [67]. This was a single-arm,
open-label, phase I, dose-escalation study. The primary endpoint
was the determination of the MTD. Secondary endpoints included
safety, pharmacokinetic profile, and efficacy. Lenvatinib wasadministered once daily, using a 28-day cycle and beginning with
a 0.2 mg/day dose. The starting dose was based on preclinical tox-
icology studies and was increased with an accelerated design until
the MTD was reached. The dose-limiting toxicity was grade 3 pro-
teinuria at the 32 mg dose of lenvatinib. The MTD was determined
to be 25 mg. The most common adverse events were hypertension
(40%), proteinuria (26%), diarrhea (45%), nausea (37%), stomatitis
(32%), and vomiting (23%). Antitumor activity included partial
response in 9% of patients and stable disease in 46%.
Phase I study of lenvatinib combined with carboplatin and paclitaxel
in patients with non-small cell lung cancer (NSCLC)
In this phase I study, 28 patients with advanced or metastatic
NSCLC received lenvatinib twice daily with carboplatin every
3 weeks, beginning with a 6 mg dose twice daily [68]. Six patients
were enrolled per dose level of lenvatinib. The primary endpoint
was the MTD. When the MTD was reached, the patient cohort
was expanded to 16 patients, and safety, pharmacokinetics, phar-
macodynamics, and antitumor effects were evaluated. Dose-
limiting toxicities, which included febrile neutropenia and gingival
infection, occurred at the 6 mg twice-daily dose. The MTD was
determined to be 4 mg twice daily. At the MTD for lenvatinib,
the most common adverse events were thrombocytopenia (100%)
and neutropenia, leukopenia, peripheral sensory neuropathy,
arthralgia, and alopecia (95% each). Other common toxicities of
any grade included proteinuria (77%), hypertension (73%), and
nausea (82%). Gastrointestinal adverse events including diarrhea,
constipation, decreased appetite each occurred in 77% of patients.
The most common grade 3 or 4 toxicities were neutropenia
(95%), leukopenia (50%), hypertension (36%), thrombocytopenia
(27%), and febrile neutropenia (23%). The pharmacokinetics of len-
vatinib were not altered by concomitant administration of carbo-
platin and paclitaxel. Biomarker analysis revealed that VEGF,
interleukin 8 (IL-8), and SDF1a were increased from baseline dur-
ing the first cycle of treatment. Lenvatinib showed promising anti-
tumor activity, with the majority of patients experiencing tumor
shrinkage. The overall RR was 68%, with a median duration of
response of 7.9 months. The median PFS was 9.0 months. At the
MTD, 1 patient experienced a complete response and 14 (64%)
had a partial response.
Phase Ib trial of lenvatinib in combination with everolimus for
metastatic renal cell carcinoma (RCC)
A total of 20 patients with advanced unresectable or metastatic
RCC and ECOG performance status 0 to 1 were enrolled in a com-
bination trial of lenvatinib and everolimus [69]. The starting dose
of lenvatinib was 12 mg once daily with everolimus 5 mg once
daily, administered in a 28-day cycle using a conventional 3 + 3
dose-escalation design. The MTD was determined to be once-
daily lenvatinib 18 mg plus everolimus 5 mg. The most common
treatment-related adverse events included fatigue (60%), mucosal
inflammation (50%), proteinuria (15%), diarrhea (10%), vomiting
(5%), hypertension (40%), and nausea (40%). Antitumor effects
included partial responses in 33% of patients and stable disease
in 50%.
Clinical trials with lenvatinib in thyroid cancer
Three clinical trials—2 phase II and 1 phase III—have evaluated
lenvatinib in MTC and RAI-refractory DTC (Table 4) [41,70–75]. The
phase II international trial of lenvatinib (NCT00784303) included 2
cohorts that were reported separately for progressive MTC and
DTC. In the MTC cohort, the partial response rate was 36% and
PFS was 9 months [74]. In patients with progressive DTC, the
Table 4
Clinical trials of lenvatinib in thyroid cancer.
Trial Phase Patient population Study description Primary endpoint Secondary
endpoint
Status of
trial
NCT01321554/SELECT
trial (study of E7080
lenvatinib in
differentiated cancer of
the thyroid) [70]
III Advanced RAI-
refractory DTC with
documented
evidence of disease
progression
Multicenter, randomized, double-
blind, placebo-controlled study
comparing lenvatinib 24 mg by
continuous once-daily dosing versus
placebo
PFS ORR Completed/
results
published
[41]
NCT01728623 [71] II Advanced thyroid
cancer
Study evaluating the safety, efficacy,
and pharmacokinetics of lenvatinib
given once daily
Number of patients with
nonserious AEs and SAEs
Change from baseline in
hematology, blood
biochemistry, urinalysis,
vital signs, ECG, and
physical exam
PFS
OS
Closed/
results
presented
[73]
NCT00784303 [72] II MTC or RAI-
refractory
unresectable DTC
Study evaluating the safety and
efficacy of lenvatinib
Objective tumor RR
according to RECIST
AEs
Laboratory
assessments
ECG
PFS
Duration of
response
Time to response
OS
Pharmacokinetics
Completed/
results
published
[74,75]
AEs = adverse events; DTC = differentiated thyroid cancer; ECG = electrocardiogram; MTC = medullary thyroid cancer; ORR = overall response rate; OS = overall survival;
PFS = progression-free survival; RAI = radioiodine; RECIST = response evaluation criteria in solid tumors; RR = response rate; SAEs = serious adverse events.
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Forty-three patients with thyroid cancer, including ATC, were
included in a phase II trial conducted in Japan [73]. Of 11 ATC
patients, 3 (27%) obtained an objective response. Median
progression-free and overall survival were 7.4 and 10.6 months,
respectively.
The results of the phase III trial (SELECT) were recently pub-
lished [41]; this randomized, double-blind, placebo-controlled
study evaluated the efficacy of lenvatinib in 392 patients with
RAI-refractory DTC with disease progression. Patients previously
treated with 1 TKI were eligible for this study. The primary end-
point was PFS. Secondary endpoints included overall RR, overall
survival, and safety. Treatment with lenvatinib (n = 261) signifi-
cantly prolonged PFS compared with placebo (n = 131) (HR: 0.21;
99% CI: 0.14–0.31; P < 0.001). Median PFS in patients receiving len-
vatinib was 18.3 months versus 3.6 months in those patients
receiving placebo. A significant PFS advantage in the lenvatinib
armwas also seen in patients who had received one prior TKI treat-
ment. Lenvatinib also significantly improved overall RRs compared
with placebo (odds ratio 28.87; 95% CI: 12.46–66.86; P < 0.001).
The RR for lenvatinib was 64.8% versus 1.5% for placebo. In patients
receiving lenvatinib, complete responses were observed in 1.5%
and partial responses in 63.2% of patients. In both groups, the med-
ian overall survival has not been reached, possibly because of the
crossover design between the 2 groups. However, in a recently
reported subanalysis, overall survival was only reached in patients
>65 years old and was significantly different in the older patients,
favoring lenvatinib over placebo (HR 0.53; 95% CI 0.31–0.91;
P = 0.02) [76].
In terms of treatment-related adverse events, hypertension
(68%), diarrhea (59%), fatigue/asthenia (59%), and decreased
appetite (50%) were the most common. Dose reductions were
needed in 67.8% of patients, and 14.2% of patients discontinued
treatment due to adverse events. A total of 71 deaths occurred in
the lenvatinib group (27.2%), mostly due to disease progression
(74.6%). Fatal adverse events developed in 20 patients (7.7%), 6
of which were treatment-related (pulmonary embolism,
hemorrhagic stroke, general deterioration, and 3 cases not
otherwise specified) [41].Lenvatinib is also currently being investigated in a variety of
other malignancies, including advanced lung cancers, hepatocellu-
lar carcinoma, advanced or metastatic melanoma, endometrial
cancer, and metastatic RCCs [77–81].Conclusions
Lenvatinib is a multikinase inhibitor with potent inhibitory
activity for FGFR1. It has antiangiogenic properties through inhibi-
tion of VEGFR and FGFR as well as direct antitumor effects [56–59].
Lenvatinib was approved for RAI-refractory DTC based on its phase
III trial results. The drug also has shown encouraging efficacy in the
treatment of MTC and ATC. Further investigation of the efficacy of
lenvatinib in ATC is needed. In phase I and II clinical trials, lenva-
tinib—either alone or in combination—showed antitumor activity
in a variety of solid tumors including NSCLC, metastatic RCC, col-
orectal cancer, sarcoma, and melanoma [66–69].
The phase III trials for lenvatinib (SELECT) and sorafenib (DECI-
SION) were both multicenter, international, randomized, double-
blind, placebo-controlled studies in RAI-refractory DTC [34,41].
The primary endpoint in both studies was PFS. DECISION included
only treatment naïve patients and SELECT included patients who
were treatment naïve and those who had received 1 prior TKI. After
a median follow-up of 17.1 months in the SELECT trial, the median
PFS was 18.3 months for lenvatinib-treated patients compared to
3.6 months with placebo (P < 0.001). The objective response rate
was 65% (complete and partial responses). In the DECISION trial,
sorafenib-treated patients had a median PFS of 10.8 months com-
pared to 5.8 months with placebo after a median of 16.2 months
follow-up and the objective response rate (partial response only)
was 12%. Most patients without a partial response achieved stable
disease for 4 weeks or longer. Common treatment-related adverse
events were similar with both TKIs and included hypertension,
diarrhea, fatigue, decreased appetite, and weight loss. Hyperten-
sion was the most common adverse event in the SELECT trial,
reported in 67.8% of patients, with more severe hypertension
reported in 41.8% of patients. In the DECISION trial, hypertension
was reported in 41% of patients, with severe hypertension reported
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mon adverse event in the DECISION trial, reported in 76.3% of
patients, whereas, in the SELECT trial, it was reported in only 32%
of patients. Fatal, treatment-related adverse events occurred in 6
patients in the SELECT trial but in only 1 patient in DECISION.
These fatal adverse events in SELECT were due in part to throm-
botic events and renal failure. Whether hypertension could have
contributed to these is unknown. The possibility that these could
have been associated with poor control of hypertension plus the
fact that hypertension was so prevalent in lenvatinib-treated
patients, makes an argument for aggressive blood pressure moni-
toring and treatment. Unfortunately, a very important aspect for
cancer patients, quality of life, was not evaluated in the SELECT
trial. Further investigation in this area is warranted [34,41].
Due to the poor survival rates from unresectable, advanced, or
refractory DTC and MTC, it is important to develop effective treat-
ment approaches for these patients. In a study evaluating the effi-
cacy of salvage therapy in DTC after first-line sorafenib, the median
OS was 58.4 months after receiving another TKI as salvage therapy
compared to 28.8 months in patients who received sorafenib only
(P = 0.013) [82]. Another study evaluating the efficacy of sunitinib
therapy in 3 patients after failure of first-line sorafenib found that
patients responded to the second-line therapy and were able to
achieve a partial response or stable disease with combined PFS of
25–31 months [83]. These results demonstrate that patients con-
tinue to respond to the second-line TKI and that switching to
another agent after failure can be effective as salvage therapy.
The long PFS seen in previously treated patients in the SELECT trial
randomized to lenvatinib is important to note, although it is not
clear if these patients had progressed on the previous TKI. How-
ever, the mechanism of action of lenvatinib may allow it to be
another effective option for patients with thyroid cancer refractory
to radioactive iodine as well as other TKIs. Further investigation
regarding sequencing of the kinase inhibitors in thyroid cancer is
needed.
Lenvatinib appears to have one of the highest RRs to date in DTC
and is now approved in the US [36] and Japan for this indication.
The drug has also been approved in Japan for all subtypes of thy-
roid cancer. It is yet unclear whether this higher RR is at the
expense of higher toxicity. Nevertheless, as a multikinase inhibitor,
lenvatinib is a promising new agent for the treatment of patients
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